Discover the latest insights on the intriguing lack of correlation between transglutaminase 2 antibody levels and celiac disease symptoms or incidental endoscopic findings at diagnosis.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Measured levels of positive transglutaminase 2 antibodies are not associated with presentation or incidental endoscopic findings at celiac disease diagnosis.
Katunin et al., Scand J Gastroenterol 2024
DOI: 10.1080/00365521.2023.2298709
Study Summary:
A study investigated the relationship between transglutaminase antibody (TGA) levels and clinical characteristics, including non-celiac endoscopic findings, in 450 patients diagnosed with celiac disease. The patients were categorized based on their TGA levels: high positive (>10x ULN, n=164), moderately positive (1-10x ULN, n=219), and negative (n=67).
Key Findings:
- The median age of patients was 50 years, with 60% being women.
- Patients with negative TGA were older and had more frequent weight loss and abdominal pain or dyspepsia compared to those with moderate or high TGA levels.
- No significant differences were found in sex, BMI, or other symptoms across the groups.
- Endoscopic findings included one case of esophageal adenocarcinoma and various other conditions, but these were not associated with TGA levels.
Importance:
This study suggests that while TGA levels can be used for non-invasive diagnosis of celiac disease, they do not correlate with the severity of the disease or the risk of co-morbidities, as evidenced by endoscopic findings. The lack of association between TGA levels and incidental endoscopic findings, including malignancies, is particularly noteworthy.
Contribution to Literature:
The research contributes to the understanding of celiac disease diagnosis by indicating that TGA levels, although useful for diagnosis, may not reflect disease severity or predict associated conditions. This is important for clinicians considering the management and further investigation of patients with varying TGA levels.